G42 Healthcare offers first certified proteomics site in EMEA region

Image: G42 Healthcare

G42 Healthcare’s Somalogic Proteomics Laboratory, part of the Omics Centre of Excellence, is now officially certified with the SomaScan Discovery Assay, making it the first certified proteomics site in EMEA region.

Proteomics is the study of the interactions, function, composition, and structures of proteins and their cellular activities.

This achievement comes on the heels of the recent launch of M42, a tech-enabled, integrated healthcare company created through the coming together of G42 Healthcare and Mubadala Health.

G42 Healthcare builds on alliance with SomaLogic

The development builds on the recent alliance between G42 Healthcare – a leading Abu Dhabi-based AI health-tech company, and SomaLogic, a leader in data-driven proteomics, which is the study of the interactions, function, composition, and structures of proteins and their cellular activities.

G42 Healthcare earned the certification upon passing the SomaSignal Assay performance requirements, spearheaded by SomaLogic.

#G42Healthcare is driving omics, precision medicine, and population health at scale.

Our Omics Centre of Excellence in #AbuDhabi is the region’s largest and most advanced omics facility, offering clinical & consumer #genomics, and #biobanking.

Know more: https://t.co/I5SS8WgrM7 pic.twitter.com/MolhZ6rlX4

— G42 Healthcare (@G42_Healthcare) June 13, 2023

The certification equips the Abu Dhabi-based healthcare company to support and drive clinical decisions as well as future development of tests using genomic, proteomic and clinical characteristics. Both teams are committed to develop future protein signatures for the people of the UAE, including validating tests that can predict cardiovascular risk four years ahead of time, which will have huge impact on personalised treatments and reduce the long-term cost to healthcare providers.

The SomaScan platform was designed as a universal platform, which can be applied across research and discovery, translational research, biopharmaceutical development, and clinical applications.

G42 Healthcare and SomaLogic also plan to collaborate on business development, strategy, and applications for the life sciences and healthcare markets, including enabling SomaSignal tests in UAE, Saudi Arabia, GCC and selected broader territories.